Full Year 2023 Investor Presentation

146 Investor presentation Full year 2023 Rare disease segment has lower profitability driven by higher investments in R&D DKK billion Diabetes and Obesity care P&L - full year 2023 Rare disease P&L - full year 2023 DKK billion 240 -14% 200 -24% 160 120 80 60 40 Sales ratios 20 20 15 -13% 10 -2% 0% 46% 5 -31% -25% -26% Novo NordiskⓇ Sales ratios -2% +1% 17% 0 0 Sales COGS S&D R&D Admin ΟΟΙ OP Sales COGS S&D R&D Admin ΟΟΙ OP P&L: Profit and Loss; COGS: Cost of goods sold; OOI: Other operating income; OP: Operating profit; S&D: Sales and distribution costs; R&D: Research and development costs; Admin: Administrative costs

View entire presentation